MORAb 066

Drug Profile

MORAb 066

Alternative Names: Anticancer monoclonal antibody (MORAb-066) - Janssen Biotech/Morphotek; MORAb-006

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor Ortho Biotech
  • Developer Morphotek
  • Class Anti-inflammatories; Anticoagulants; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Thromboplastin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 01 Aug 2018 Discontinued - Phase-I for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)
  • 01 Aug 2018 Discontinued - Phase-I for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)
  • 01 Aug 2018 Discontinued - Phase-I for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Eisai pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top